• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Beam Therapeutics Inc.

    4/18/25 4:05:05 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email
    DEFA14A 1 beam_2025_notice_not_xbr.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material under §240.14a-12

     

    BEAM THERAPEUTICS INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

     

     

     

     

     

     

    ☒

    No fee required.

     

     

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 5, 2024 Your Vote Counts! BEAM THERAPEUTICS INC. 2024 Annual Meeting June 5, 2024 11:30 AM EDT Virtual Meeting Site: www.virtualshareholdermeeting.com/BEAM2024. Beam THERAPEUTICS BEAM THERAPEUTICS INC 238 MAIN STREET ‘CAMBRIDGE, MA 02142 V39070-P05844 You invested in BEAM THERAPEUTICS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 5, 2024. Get informed before you vote View the Notice and Proxy Statement and 2023 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* Vote on June 5, 2024 11:30 AM, EDT Visit: www.virtualshareholdermeeting.com/BEAM2024 Vote in Advance of the Meeting Vote by June 4, 2024 11:59 PM ET Visit www.ProxyVote.com *Please check the meeting materials for any special requirements for meeting attendance.img96016227_0.jpg


     

    img96016227_1.jpg

    ostponement, or adjournment thereof. For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings”. V3907 1-P05844


    Get the next $BEAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    12/15/2023$35.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beam Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

      3/28/25 8:10:19 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Scotiabank with a new price target

      Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

      3/10/25 11:54:09 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

      1/29/25 7:35:38 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    SEC Filings

    See more
    • Beam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      6/6/25 4:05:16 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

      SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      5/15/25 5:04:40 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

      SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      5/13/25 3:45:40 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Walsh Kathleen E

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:30 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shaw Christi

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:26 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fishman Mark

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:28 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

      CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation from the FDA emphasizes the importance of new treatment options for this debilitating disease, a

      6/3/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effecti

      5/29/25 4:01:00 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

      CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

      12/4/24 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

      CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

      12/14/23 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/12/24 9:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/7/24 9:56:02 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      10/17/24 11:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Financials

    Live finance-specific insights

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

      Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

      5/14/25 9:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

      Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

      3/10/25 6:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care